Company profile: 858 Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule drug development targeting oncology and immunology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 858 Therapeutics
Valitor Bio
HQ: United States
Website
- Description: Provider of novel methods to modify therapeutic proteins for control over pharmacological properties, including VLTR-559, a long-acting treatment for wet age-related macular degeneration designed to extend a single dose to six months or more; VLTR-557, a long-acting anti-VEGF biologic with potential six-month efficacy from one intravitreal injection; and Multivalent Polymer (MVP) Technology to enhance potency, durability, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valitor Bio company profile →
iOnctura
HQ: Switzerland
Website
- Description: Provider of clinical-stage biopharmaceutical therapies targeting immunosuppression in the tumor microenvironment to improve immune checkpoint therapies. Pipeline includes Roginolisib (IOA-244), a PI3Kδ inhibitor in Phase Ib/II for solid tumors and hematological malignancies; IOA-289, an autotaxin inhibitor in Phase Ib/II for pancreatic and other CAF-driven tumors; and preclinical IOA-359 (TGF-β) and IOA-237 (CD73 mAb).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iOnctura company profile →
HistoGeneX
HQ: Belgium
Website
- Description: Provider of biomarker technologies for translational and clinical research via CAP, CLIA, and BELAC-accredited laboratories. Offers integrated sample management and logistics, biomarker strategy support, oncology assays; flow cytometry, histopathology, genomics, immunoassays; plus CellEngine cytometry analysis software and Olink PEA protein biomarker quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HistoGeneX company profile →
Olaris
HQ: United States
Website
- Description: Provider of metabolomics and machine learning-based disease diagnosis and treatment solutions, including Olaris CEREBRO for metabolite profiling to identify individual molecular profiles, myOLARIS diagnostics, a suite of in vitro diagnostic products to optimize patient-specific treatments and outcomes, and Biomarkers of Response (BoRs) technology to determine which patients will benefit from specific therapies and reduce adverse events.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Olaris company profile →
Nativis
HQ: United States
Website
- Description: Provider of therapeutic modalities in development for the treatment of serious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nativis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 858 Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 858 Therapeutics
2.2 - Growth funds investing in similar companies to 858 Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 858 Therapeutics
4.2 - Public trading comparable groups for 858 Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →